Liquidia stock names Russell Schundler chief strategy officer
Published on 11/20/2026 at 22:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership Change Adds Strategy Role
- Russell Schundler combines the chief strategy officer and general counsel roles.
- He has served as Liquidia's general counsel since March 2021.
- Liquidia is developing and commercializing treatments for cardiopulmonary diseases, including YUTREPIA.
Liquidia Corporation's board appointed Russell Schundler chief strategy officer and general counsel on November 12, with the change taking effect on November 16, according to a November 18 report by MarketScreener, citing S&P Capital IQ.
Expanded Role For Schundler
Schundler has been Liquidia's general counsel since March 2021. The expanded mandate places strategy and legal leadership under one executive as the biopharmaceutical company develops and commercializes treatments for cardiopulmonary diseases.
Liquidia's lead product, YUTREPIA, is an inhaled treprostinil treatment for pulmonary arterial hypertension. The company also develops products for pulmonary hypertension associated with interstitial lung disease and other applications of its PRINT technology.
Liquidia stock traded at 49.69 euros on Lang & Schwarz at 22:34 CET on Friday, November 20, 2026.
Liquidia Corporation
- ISIN: US53635D2027
- Ticker: LQDA
- Home exchange: Nasdaq
- Sector: Pharmaceuticals
- Lang & Schwarz quote: 49.69 euros at 22:34 CET on Friday, November 20, 2026
The Nasdaq Composite is the broader US market setting for Liquidia stock.
